Video -

Vironova - virus diagnostics and antiviral drug development

Get an impression of Vironova's ground breaking virus detection and analysis software. It provides tools for rapid and objective virus diagnostics and fast screenng of potential antiviral substances. It's a technology which can eliminate the viral threat - where ever its origin may be.
go to media item
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
File format:
.mp4
Length:
1:31
Download

Topics

  • Medical research

Categories

  • key tags

Contacts

Mohammed Homman

Chairman of the Board

Related content

Vironova CEO explains "Virus Art" on national TV

On December 10th, Vironova CEO, Mohammed Homman, presented Vironova’s "Virus Art" collection on Swedish national TV (TV4). The exclusive glass art collection with virus theme was created by the renowned glass master Jim Johnsson as a joint effort with Vironova to raise funds to the company´s fight against viral diseases.

VIRONOVA EXTENDS ITS HIV DRUG DEVELOPMENT PIPELINE

Vironova today announced it has reached an agreement with University of Maryland, Baltimore County (UMBC) regarding transfer of rights to patents concerning certain substances and know-how for the development of new drugs against HIV. Under the terms of the agreement Vironova is granted exclusive worldwide rights to two patent families owned by UMBC.

VIRONOVA genomför företrädesemission

Vironova meddelar att idag är första dagen att teckna aktier i den företrädesemission som stänger den 17 juli. Målet med emissionen är att tillföra bolaget ca SEK 10 miljoner . Pengarna kommer att användas till att finansiera marknadsföringen, försäljningen och ökat utbud av analytjänster samt den fortsatta utvecklingen av bolagets teknologiplattform för datoriserad identifiering av virus.